Primary Progressive Multiple Sclerosis: New Therapeutic Approaches
Neuropsychopharmacology Reports, Volume 45, Issue 3, September 2025.Primary progressive MS affects 10%–15% of MS patients, causing irreversible neurological impairment. Drugs like ocrelizumab show promise, while high‐dose biotin, simvastatin, and coenzyme Q10 are under investigation. Gene therapy and stem cell treatments also show potential.
Morteza Rajabi +8 more
wiley +1 more source
In vitro unresponsiveness to autologous sequences of the immunopathogenic autoantigen, S-antigen. [PDF]
, 1991 Steven P. Fling +2 more
openalex +1 more source
New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond
Annals of Neurology, Volume 98, Issue 2, Page 317-328, August 2025.The advances achieved against multiple sclerosis (MS) represent one of the great success stories of modern molecular medicine. The development of therapies with increasing selectivity and safety, guided by gains in understanding the fundamental immunology, neurobiology, genetics, and triggers of this disease, have broadened the traditional focus on ...
Joseph J. Sabatino Jr. +2 more
wiley +1 more source
Pancreas in recent onset insulin-dependent diabetes mellitus: changes in HLA, adhesion molecules and autoantigens, restricted T cell receptor Vbeta usage and cytokine profile [PDF]
, 1994 N Somoza +10 more
openalex +1 more source
Sita‐ and saxagliptin use and autoantibodies to autoimmune bullous diseases: A cross‐sectional study
Journal of the European Academy of Dermatology and Venereology, EarlyView.
Sören Dräger +8 more
wiley +1 more source
Current and Emerging Autoantibodies in Ulcerative Colitis
European Journal of Immunology, Volume 55, Issue 8, August 2025.Autoantibodies in ulcerative colitis target neutrophil and mucosal components, including NETs, goblet cells, and integrins‐offering insight into disease pathophysiology. Understanding these interactions may support biomarker development, enable earlier diagnosis, aid patient stratification, and drive future therapeutic innovation.
Erick A. Mendieta‐Escalante +2 more
wiley +1 more source
Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus. [PDF]
, 1994 John Kim +10 more
openalex +1 more source
Revolutionizing Autoimmune Research: The Role of Caveolin‐1
Immunity, Inflammation and Disease, Volume 13, Issue 8, August 2025.ABSTRACT Introduction Caveolins (Cav) include Cav‐1, Cav‐2, and Cav‐3, with Cav‐1 being the most studied due to its prominent role as a major component of plasma membrane caveolae. Cav‐1 is involved in a wide range of cellular functions and plays a key role in regulating signaling pathways related to immune responses and inflammation.
Yanan Gao +8 more
wiley +1 more source
Malignancies Presenting With ANCA Positivity: Two Case Reports and Diagnostic Considerations
Immunity, Inflammation and Disease, Volume 13, Issue 8, August 2025.ABSTRACT Background ANCA‐associated vasculitides (AAV) are small‐vessel inflammatory disorders characterized by the presence of anti‐neutrophil cytoplasmic antibodies (ANCA), including those against proteinase 3 (PR3) and myeloperoxidase (MPO).
Min Zhao, Yue Lu, Ling Li
wiley +1 more source